Quel Launches Telemedicine GLP-1 Prescribing for Addiction in 41 States

Quel’s service extends an observational program first described at Caron in 2025, where semaglutide was added to standard addiction care for patients with co-occurring obesity. The company reports that prescriptions target alcohol, opioid, and behavioral addictions without requiring a diabetes or weight-loss diagnosis. No randomized data from the Caron cohort have been published.

Emerging trials, including a 2024 JAMA Psychiatry systematic review of seven small studies, show 20–40 % reductions in alcohol craving scores with GLP-1 agents versus placebo, yet sample sizes remain under 100 and follow-up rarely exceeds 12 weeks. Larger phase-2 trials registered on ClinicalTrials.gov now target alcohol-use disorder, but none have reported primary endpoints for opioid or stimulant use.

Off-label prescribing carries unmeasured risks: gastrointestinal adverse events occur in 40–50 % of users, and long-term cardiovascular or psychiatric safety data in non-obese addiction populations are absent. FDA has issued no enforcement guidance on this specific use, leaving state medical boards to determine whether telemedicine platforms meet standard-of-care thresholds.

Next steps hinge on two pending multicenter RCTs expected to report in 2027; positive results could prompt an FDA supplemental indication, while negative findings would likely trigger payer restrictions and state-level scrutiny of direct-to-consumer GLP-1 addiction claims.